Concord Biotech (CONCORDBIO) | Stock Overview & Key Data
Concord Biotech Performance Comparison
Stock Range
Today's Range
Low: ₹1,523.90
High: ₹1,580.40
on September 26, 2025
52 Week Range
Low: ₹1,345.00
High: ₹2,451.70
on May 9, 2025
on February 10, 2025
All-Time High: ₹2,664.00 on September 16, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR163.9B
EPS
33.97
P/E Ratio (TTM)
46.08
Forward P/E
31.35
P/B Ratio
9.03
PEG Ratio
-1.76
Div. Yield
0.44%
ROE
20.50%
Beta
0.952
Debt to Equity
0.16
Financial Highlights
Profitability
Gross Margin
77.89%
Operating Margin
21.38%
Profit Margin
29.97%
Returns and Earnings
Return on Assets (TTM)
18.27%
Return on Equity (TTM)
20.50%
EBITDA
INR5.3B
Net Income (TTM)
INR3.6B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR113.58
Quarterly Revenue Growth (YoY)
-5.50%
Quarterly Earnings Growth (YoY)
-26.10%
Dividend Information
Last 12-Month Dividend
₹8.75
Current Dividend Yield
0.44%
3-Year Average Dividend Yield
0.56%
3-Year Average Annual Dividend
₹2.92
3-Year Total Dividends
₹8.75
Ex-Dividend Date
June 21, 2024
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Concord Biotech CONCORDBIO | 163.87B Mid-cap | -4.13% | -7.53% | -12.44% | -6.00% | -26.04% | -22.39% | 68.56% | 68.56% |
| Biocon BIOCON | 455.97B Large-cap | -3.38% | -1.11% | 1.29% | 2.24% | -3.48% | -3.50% | 22.34% | -21.36% |
| OneSource Specialty ONESOURCE | 207.35B Large-cap | -6.19% | -7.37% | -12.74% | 1.43% | 2.04% | 2.04% | 2.04% | 2.04% |
| Blue Jet Healthcare BLUEJET | 112.12B Mid-cap | -2.70% | -9.74% | -24.50% | -24.45% | 15.14% | 29.07% | 70.54% | 70.54% |
| Supriya Lifescience SUPRIYA | 59.72B Mid-cap | 7.61% | 11.94% | 10.49% | 1.97% | -2.01% | 31.41% | 147.06% | 53.26% |
| Dishman Carbogen DCAL | 44.90B Small-cap | 3.09% | 5.56% | 18.69% | 30.62% | 3.51% | 60.91% | 206.33% | 80.50% |
Ownership & Short Interest
Insider Ownership
74.83%
Institutional Ownership
13.21%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
118K
Average 90-Day Volume
111K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is CONCORDBIO's 52-week high and low?
- In the last 52 weeks, Concord Biotech reached a high of ₹2,451.70 (on February 10, 2025) and a low of ₹1,345.00 (on May 9, 2025).
- What is the market cap and P/E ratio for CONCORDBIO?
- Curious about Concord Biotech's size and valuation? Its market capitalization stands at 163.87B. When it comes to valuation, the P/E ratio (trailing twelve months) is 46.08, and the forward P/E (looking ahead) is 31.35.
- Does CONCORDBIO pay dividends? If so, what's the yield?
- Yes, Concord Biotech is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.44%, and the company has paid an average of ₹2.92 per share annually over the past 3 years.
- Who are Concord Biotech's main competitors or similar companies to consider before investing?
When looking at Concord Biotech, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Biocon
BIOCON455.97B Healthcare Biotechnology -3.50% 22.34% OneSource Specialty
ONESOURCE207.35B Healthcare Biotechnology 2.04% 2.04% Blue Jet Healthcare
BLUEJET112.12B Healthcare Biotechnology 29.07% 70.54% Supriya Lifescience
SUPRIYA59.72B Healthcare Biotechnology 31.41% 147.06% Dishman Carbogen
DCAL44.90B Healthcare Biotechnology 60.91% 206.33% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Concord Biotech Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Concord Biotech's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 20.50%, the Debt to Equity ratio from the most recent quarter is 0.16, and its Gross Profit Margin stands at 77.89%.
- What is the recent revenue and earnings growth for CONCORDBIO?
- Looking at Concord Biotech's growth, its revenue over the trailing twelve months (TTM) was INR12B. Compared to the same quarter last year (YoY), quarterly revenue grew by -5.50%, and quarterly earnings saw a YoY growth of -26.10%.
- How much of CONCORDBIO stock is held by insiders and institutions?
- Wondering who owns Concord Biotech stock? Company insiders (like executives and directors) hold about 74.83% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 13.21%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.